Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04655222 (ClinicalTrials.gov)	May 1, 2021	30/11/2020	Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program	Non-interventional Safety Study to Investigate Pregnancy Outcomes in Female Patients Exposed to SC Peginterferon Beta-1a and IM Interferon Beta-1a Reported in a German Patient Support Program	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon Beta Therapy	Biogen	NULL	Completed	18 Years	N/A	Female	470		Germany
2	NCT03347370 (ClinicalTrials.gov)	November 27, 2017	16/11/2017	A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis	Subcutaneous (SC) Interferon Beta Therapy in Multiple Sclerosis Patients and Characterization of Injection Site Reactions and Flu-Like Symptoms Under Daily Practice Setting	Multiple Sclerosis, Relapsing-Remitting	Drug: SC Peginterferon beta-1a;Drug: SC interferon beta-1a;Drug: SC interferon beta-1b	Biogen	AMS Advanced Medical Services GmbH	Completed	18 Years	N/A	All	626		Germany
3	NCT00493077 (ClinicalTrials.gov)	May 2004	25/6/2007	Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy	A Swedish Multi-Centre, Prospective, Open Label Study: Safety of Avonex Treatment in Multiple Sclerosis Patients Who Are NAB Positive on Previous s.c Interferon Beta Therapy	Multiple Sclerosis	Drug: low immunogenic interferon-beta-1a	Biogen Idec	NULL	Completed	18 Years	55 Years	Both	3	Phase 4	Sweden